Text and Data Mining valid from 2019-03-20
Received: 20 November 2018
Revised: 6 February 2019
Accepted: 6 February 2019
First Online: 20 March 2019
: Dr. Moran reports he is an employee of Pfizer UK Ltd. This employment has no relationship with the submitted publication. All remaining authors declare no competing interests.
: Patient data was generated using anonymised identifiers and held within the Northern Ireland Biobank and by the University of Liverpool Department of Molecular and Clinical Cancer Medicine.
: Data is held within the Northern Ireland Biobank and the University of Liverpool Department of Molecular and Clinical Cancer Medicine and is available on application.
: The study was conducted according to the Good Clinical Practice guidelines and the Declaration of Helsinki. Ethical approval for work in the Northern Ireland OPSCC cohort was granted under the Northern Ireland Biobank (NIB 11/0001). The Two distinct OPSCC cohorts diagnosed within the Liverpool Head and Neck Oncology Service from 1998 to 2009 and 2002 to 2011, respectively, were accessed under prior ethical approval (South Sefton Research Ethic Committee, EC·47·01–6; North West Five Research Ethics Committee, EC·09·H1010·5, REC 11/NQ/0452 and REC 16/LO/1726).